Influence of baseline demographics/disease characteristics on efficacy of an oral selective TYK2 inhibitor, BMS-986165, in patients with moderate to severe plaque psoriasis: Phase 2, randomized, placebo-controlled trial

Main Article Content

K Gordon
K Papp
M Gooderman
D Thaci
P Foley
A Morita
S Kundu
R Kisa
A Napoli
S Banerjee

Keywords

psoriasis, tyrosine kinase 2 inhibitor

Abstract

Abstract not available.

References

1. Korman NJ et al. Dermatol Online J. 2015;21:pii:13030/qt1x16v3dg.

2. Tokarski JS et al. J Biol Chem. 2015;290:11061-11074.

3. Gillooly K et al. Arthritis Rheumatol. 2016;68(suppl 10):abstract 11L.

4. Shaw MH et al. Proc Natl Acad Sci U S A. 2003;100:11594-11599.

5. Harden JL et al. J Autoimmun. 2015;64:66-73.

6. Papp K et al. N Engl J Med. 2018;379:1313-1321.

7. Hongbo Y et al. J Investig Dermatol. 2005;125:659-664.

8. European Medicines Agency. Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. 2004. https://www.ema.europa.eu/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-indicated-treatment-psoriasis_en.pdf. Accessed December 17, 2018.